Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

After hours: October 18 at 7:51 PM EDT Loading Chart for SAVA ...

WASHINGTON, Sept 26 (Reuters) - Shares of Cassava Sciences (SAVA.O), opens new tab fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the ...

Throughout the world, an estimated 800 million people consider cassava root a staple part of their diet. This starchy tuber—also known as yuca, Brazilian arrowroot, and manioc—first originated in ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...

Cassava Sciences paid $40m after the SEC raised a case about alleged misleading data and misleading investors after a Phase IIb study of its Alzheimer’s drug. Image credit: Shutterstock / Tada Images ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...